Shenzhen Lifotronic Technology Co
Shenzhen Lifotronic Technology Co., Ltd. research, develops, manufactures, and markets medical devices for diagnostics, therapy, clinical medicine, skin, and human health related purposes in China. The company offers IVD products, such as HPLC, ECLIA, and hematology system; rapid test, molecular and POCT diagnostics. It also offers therapeutic products comprising respiratory and ICU, and wound ca… Read more
Shenzhen Lifotronic Technology Co (688389) - Total Assets
Latest total assets as of September 2025: CN¥2.65 Billion CNY
Based on the latest financial reports, Shenzhen Lifotronic Technology Co (688389) holds total assets worth CN¥2.65 Billion CNY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Shenzhen Lifotronic Technology Co - Total Assets Trend (2016–2024)
This chart illustrates how Shenzhen Lifotronic Technology Co’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Shenzhen Lifotronic Technology Co - Asset Composition Analysis
Current Asset Composition (December 2024)
Shenzhen Lifotronic Technology Co's total assets of CN¥2.65 Billion consist of 75.4% current assets and 24.6% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 59.6% |
| Accounts Receivable | CN¥187.91 Million | 6.5% |
| Inventory | CN¥172.77 Million | 6.0% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥100.56 Million | 3.5% |
| Goodwill | CN¥36.20 Million | 1.3% |
Asset Composition Trend (2016–2024)
This chart illustrates how Shenzhen Lifotronic Technology Co's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Shenzhen Lifotronic Technology Co's current assets represent 75.4% of total assets in 2024, a decrease from 88.8% in 2016.
- Cash Position: Cash and equivalents constituted 59.6% of total assets in 2024, down from 82.5% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, an increase from 3.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 6.5% of total assets.
Shenzhen Lifotronic Technology Co Competitors by Total Assets
Key competitors of Shenzhen Lifotronic Technology Co based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shanghai Kehua Bio-Engineering Co Ltd
SHE:002022
|
China | CN¥5.17 Billion |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.67 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥4.55 Billion |
|
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932
|
China | CN¥6.10 Billion |
|
Shinhung
KO:004080
|
Korea | ₩153.50 Billion |
|
UMediC Group Berhad
KLSE:0256
|
Malaysia | RM94.93 Million |
|
Osang Healthcare Co.,Ltd
KQ:036220
|
Korea | ₩287.70 Billion |
|
HansBiomed Corporation
KQ:042520
|
Korea | ₩126.41 Billion |
Shenzhen Lifotronic Technology Co - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Shenzhen Lifotronic Technology Co generates 0.40x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Excellent ROA - For every $100 in assets, Shenzhen Lifotronic Technology Co generates $ 11.93 in net profit.
Shenzhen Lifotronic Technology Co - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.30 | 2.44 | 7.22 |
| Quick Ratio | 3.00 | 2.25 | 6.67 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.25 Billion | CN¥ 1.25 Billion | CN¥ 824.93 Million |
Shenzhen Lifotronic Technology Co - Advanced Valuation Insights
This section examines the relationship between Shenzhen Lifotronic Technology Co's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.73 |
| Latest Market Cap to Assets Ratio | 0.13 |
| Asset Growth Rate (YoY) | 24.2% |
| Total Assets | CN¥2.89 Billion |
| Market Capitalization | $370.56 Million USD |
Valuation Analysis
Below Book Valuation: The market values Shenzhen Lifotronic Technology Co's assets below their book value (0.13 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Shenzhen Lifotronic Technology Co's assets grew by 24.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Shenzhen Lifotronic Technology Co (2016–2024)
The table below shows the annual total assets of Shenzhen Lifotronic Technology Co from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.89 Billion | +24.16% |
| 2023-12-31 | CN¥2.33 Billion | +28.06% |
| 2022-12-31 | CN¥1.82 Billion | +23.47% |
| 2021-12-31 | CN¥1.47 Billion | +14.34% |
| 2020-12-31 | CN¥1.29 Billion | +9.38% |
| 2019-12-31 | CN¥1.18 Billion | +45.21% |
| 2018-12-31 | CN¥811.93 Million | +14.29% |
| 2017-12-31 | CN¥710.40 Million | +42.79% |
| 2016-12-31 | CN¥497.52 Million | -- |